Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,444 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06505824RecruitingPhase 1
Study of BL-M14D1 for advanced lung cancer and other solid tumors
This trial tests a new drug, BL-M14D1, for people with advanced small cell lung cancer, neuroendocrine tumors, or other solid tumors that have no standard treatment. The goal is to see if the drug is safe and possibly effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06488950RecruitingEarly Phase 1
TIL therapy for advanced solid tumors
This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.
ShanghaiAges 18–75 - NCT06493864RecruitingPhase 1
BL-B16D1 for advanced breast cancer and solid tumors
This trial tests a new drug called BL-B16D1 for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06468358RecruitingPhase 1/Phase 2
LB1410 and LB4330 for advanced solid tumors
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06474455RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for advanced solid tumors
This trial tests a new drug called SHR-9839 combined with other cancer treatments for people with advanced solid tumors, including a certain type of lung cancer. The goal is to see if the combination is safe and effective against the cancer.
Zhengzhou, HenanAges 18–75 - NCT06475300RecruitingPhase 2
BL-B01D1 plus immunotherapy for advanced lung and throat cancers
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
Guangzhou, GuangdongAges 18 years+ - NCT06462794RecruitingPhase 1
Study of CX-801 for advanced solid tumors
This trial tests a new drug called CX-801 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06444815RecruitingPhase 1
Study of VET3-TGI for advanced solid tumors
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Los Angeles, CaliforniaAges 18 years+ - NCT05055609RecruitingPhase 1
Study drug TRE-515 for advanced solid tumors using PET scans
This Phase 1 trial tests how safe TRE-515 is, what dose can be used, and how the drug moves through the body, including using PET scans. It’s for adults with advanced solid cancers that have stopped responding to standard treatment.
Santa Monica, CaliforniaAges 18 years+ - NCT06439888RecruitingPhase 1/Phase 2
Immune cells plus radiation for limited-stage cancer spread
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
LyonAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06424665RecruitingPhase 1
Study of FZ-AD005 for advanced solid tumors
This trial tests a new drug called FZ-AD005 for people with advanced solid tumors, especially small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). It may help if standard treatments are no longer working.
Changsha, HunanAges 18–75 - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
Phoenix, ArizonaAges 18 years+ - NCT06416007RecruitingPhase 2
Lattice radiation for large tumor palliation
This study tests a new way to deliver radiation called lattice therapy for people with large solid tumors that are causing symptoms. It aims to give a stronger radiation dose to help shrink the tumor and relieve discomfort.
Cincinnati, OhioAges 18 years+ - NCT06398418RecruitingPhase 1
Study of R-5780 with PD-1 drugs for advanced solid tumors
This trial tests a new drug called R-5780 combined with standard immunotherapy (PD-1 checkpoint inhibitors) for people with advanced skin cancers or other solid tumors that have stopped responding to treatment. The goal is to see if this combination is safe and helps fight the cancer.
Denver, ColoradoAges 18–80 - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT06384807RecruitingPhase 1/Phase 2
Study of BHV-1510 for advanced solid tumors
This trial tests a new drug, BHV-1510, alone or combined with another drug (cemiplimab), for people with advanced solid tumors that haven't responded to other treatments. It's for those who are still in fairly good health and have not had certain prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT06375187RecruitingPhase 1
GC203 TIL for advanced solid tumors
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
ShanghaiAges 18–75 - NCT06210815RecruitingPhase 1
Testing a new drug HLX42 for advanced solid tumors
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
Guangdong, GuangzhouAges 18–75 - NCT05216432RecruitingPhase 1
RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer
This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.
Tucson, ArizonaAges 18 years+ - NCT06358677RecruitingPhase 2
Tretinoin cream to prevent skin rash from EGFR drugs
This study tests whether a topical tretinoin cream can prevent the skin rash often caused by anti-EGFR drugs like panitumumab or cetuximab. It is for people with advanced solid tumors who are about to start one of these treatments.
Salt Lake City, UtahAges 18 years+ - NCT05381038RecruitingPhase 1/Phase 2
Personalized azacitidine combinations for breast or stomach cancer
This Phase 1/2 trial tests different combinations that include azacitidine, chosen based on your tumor’s lab “response markers” and past drug-sensitivity screening. It aims to find safer dosing and see whether these personalized combinations can shrink solid tumors such as breast or stomach cancer.
SingaporeAges 21–99 - NCT06302621RecruitingPhase 1
Pemigatinib plus afatinib for advanced solid tumors with FGFR changes
This trial tests two targeted drugs, pemigatinib and afatinib, together for people with advanced solid tumors that have a specific FGFR genetic change. It may be an option if standard treatments have stopped working or aren't available.
Boston, MassachusettsAges 18 years+ - NCT06276491RecruitingPhase 1
Safety study of an investigational drug for advanced cancer with the CLDN6 marker
This trial tests an investigational drug for people with advanced solid tumors, especially ovarian, fallopian tube, peritoneal, endometrial, or germ cell cancers that have a specific marker called CLDN6. The goal is to see if the drug is safe and tolerable.
Duarte, CaliforniaAges 15 years+
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,444 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.